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Insulin-like growth factor-I induces the phosphorylation
and nuclear exclusion of forkhead transcription factors
in human neuroblastoma cells
T. S. Schwab, B. B. Madison, A. R. Grauman and E. L. Feldman
Department of Neurology, University of Michigan, Ann Arbor, Michigan
Akt-mediated phosphorylation of forkhead transcription
factors is linked to growth factor-stimulated cell sur-
vival. We investigated whether the survival activity of
insulin-like growth factor-I (IGF-I) in SH-SY5Y human neu-
roblastoma (NBL) cells is associated with phosphory-
lation and/or localization changes in forkhead proteins.
IGF-I induced phosphorylation of Erks (p42/p44), FKHR
(FOXO1a) (Ser 253), FKHRL1 (FOXO3a) (Ser 256), and
Akt (Ser 473). PI3-K inhibitor, LY294002, reduced IGF-I-
stimulated phosphorylation of FKHR, FKHRL1, and Akt,
but did not affect Erk phosphorylation. Using a GFP-FKHR
construct, FKHR imported into the nucleus during growth
factor withdrawal-induced apoptosis. In addition, IGF-I
rescue from serum withdrawal-induced apoptosis is as-
sociated with a rapid export of GFP-FKHR into the cyto-
plasm. Leptomycin B, an inhibitor of Crm1-mediated nu-
clear export, decreased the level of FKHRL1 phosphory-
lation in the presence of IGF-I in vector and FKHR overex-
pressing cells, but had no effect on the phosphorylation
status of FKHR. In addition, leptomycin B prevented IGF-
I stimulated nuclear export of GFP-FKHR. These studies
show IGF-I phosphorylation of FKHR and FKHRL1 via a
PI3-K-dependent pathway in NBL cells.
Keywords: FKHR; FKHRL1; forkhead; IGF-I; IGF-IR; neurob-
lastoma.
Introduction
Neuroblastoma (NBL) is a devastating childhood can-
cer with poor prognosis for diagnosis over the age of
12 months.1,2 Although NBL accounts for 10% of all
childhood solid tumors, relatively little is known about
the molecular events leading to NBL development, pro-
gression, and metastasis.1 Furthermore, current treatment
protocols are inadequate, with metastatic disease largely
incurable. Therefore, any knowledge gained concerning
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tumorigenic properties of NBL or ways to induce apopto-
sis, leading to increased treatment efficacy, will be poten-
tially clinically beneficial. One area that has been highly
investigated is the role of growth factors in NBL develop-
ment and progression. The most studied growth factor in
NBL is nerve growth factor (NGF) which has a negative
effect on NBL cell survival and growth.3,4 In contrast,
brain derived growth factor (BDNF) protects NBL from
drug-induced apoptosis in vitro5,6 and is associated with
poor prognosis in NBL patients.7
We have recently shown that insulin-like growth
factor-I (IGF-I) signaling through its receptor (type I
IGF receptor, IGF-IR) is altered and IGF-IR expression
levels are increased in tumorigenic NBL cells. Our lab-
oratory has had a long-standing interest in the IGF-
I/IGF-IR system, and we have shown that IGF-I and
IGF-IR play important roles in NBL signaling, motil-
ity and survival, all of which occur through specific
signaling mechanisms.8–11 Ligand binding of IGF-I by
IGF-IR mediates receptor autophosphorylation, which,
in turn, enhances binding and tyrosine phosphoryla-
tion of downstream adaptor proteins.12–14 These adap-
tor proteins recruit further signaling proteins activat-
ing signaling cascades such as the phosphatidylinositol
3-kinase (PI3-K) and the mitogen-activated protein ki-
nase (MAPK) pathways. The MAPK pathway is primar-
ily involved in cellular differentiation and growth,15,16
whereas the PI3-K pathway is essential in mitogenesis,
glycogen synthesis, and motility.17–19 Interestingly, both
the PI3-K and MAPK pathways are important in protect-
ing cells from apoptosis.20 Multiple downstream effectors
of the Akt/MAPK pathways are implicated in cell survival
and apoptosis. The best characterized of these is the ser-
ine/threonine protein kinase Akt.21,22 The first report of
an anti-apoptotic effect of Akt was in cerebellar neurons in
which IGF-I treatment promoted both Akt phosphoryla-
tion and cell survival.23 A variety of studies show that Akt
is activated by PI3-K-dependent phosphorylation upon
growth factor exposure leading to cell survival.21,24–27
In addition, the use of wild type and/or dominant
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negative mutant Akt constructs provide further evidence
that Akt activation leads to protection from apoptosis22,28
(for review see.29).
Several reports show that activated Akt translocates to
the nucleus upon growth factor exposure.25,30 These data
suggest an association with nuclear proteins such as tran-
scription factors to directly regulate gene transcription.30
Studies in C. elegans show that the forkhead transcrip-
tion factor DAF-16 interacts with Akt in the nucleus.31
Currently, there are three human homologues of DAF-
16 located at chromosomal breakpoints in human tu-
mors: FKHR (FOXO1a),32,33 FKHRL1 (FOXO3a),34,35
and AFX (FOXO4).36 These human forkhead homologs
contain three sites that are phosphorylated by Akt in vitro
and appear to be phosphorylated by Akt in vivo in growth
factor-stimulated cells.37,38,38–45 Consistent with a role
for forkhead proteins in PI3-K/Akt signaling, inhibitors
of PI3-K block the growth factor-stimulated phosphory-
lation of FKHR and FKHRL1, as well as phosphorylation
and activation of Akt.38,41,44 In addition, it appears that
Akt-mediated phosphorylation of these forkhead proteins
causes translocation from the nucleus to the cytoplasm
by a Crm1 dependent mechanism.43 Forkhead protein
translocation may block apoptosis by preventing tran-
scription of genes responsible for cell death.37,37,40,46,47
Together, these studies support a model in which
PI3-K/Akt-dependent phosphorylation of forkhead pro-
teins helps mediate growth factor-stimulated cellular
survival.
Based upon the above reports, the current study ex-
amines the effect of IGF-I signal transduction on the
forkhead transcription factors (FKHR and FKHRL1) in
human SH-SY5Y NBL cells exposed to serum with-
drawal and mannitol-induced apoptotic stimuli. IGF-I
induces the phosphorylation of FKHRL1 and FKHR via a
PI3-K-dependent pathway. FKHR is predominantly lo-
calized to the nucleus upon growth factor withdrawal,
while IGF-I exposure results in FKHR export from the
nucleus to the cytoplasm. Exposure of FKHR overexpress-
ing cells to leptomycin B, a specific inhibitor of nuclear
export, reveals a decrease in the phosphorylation status of
FKHRL1, while no changes were seen in phospho-FKHR
levels. In addition, leptomycin B blocks IGF-I mediated
nuclear export of FKHR. Collectively, these data indicate
that IGF-I stimulates the phosphorylation and nuclear ex-




All cell culture reagents were purchased from GIBCO
BRL (Gaithersburg, MD) unless otherwise stated. SH-
SY5Y human NBL cells were cultured in DMEM with
10% calf serum (CS) (Hyclone Lab, Logan, UT) at 37◦C
with 10% CO2 in a humidified incubator. Human re-
combinant IGF-I was a generous gift from Cephalon,
Inc. (West Chester, PA). All other chemicals and reagents
were purchased from Sigma Chemical Company (St. Louis,
MO).
For indicated experiments, cells were transfected
with 8 µg of pCMV-Tag-2C-FKHR, pEGFP-C3-FKHR,
pCMV-Tag-2C, or pEGFP-C3 vectors using Lipofec-
tamine 2000 reagent following the manufacturer’s proto-
col. The pCMV-Tag-2C-FKHR and pEGFP-C3-FKHR
vectors were generous gifts from David Powell (Baylor
College of Medicine, Houston, Texas). The pCMV-Tag-
2C vector was purchased from Stratagene Cloning Sys-
tems (La Jolla, CA), while the pEGFP-C3 vector was pur-
chased from Clonetech Laboratories, Inc. (Palo Alto, CA).
Transfected cells were selected in 250 µg/mL geneticin
for 1 month prior to beginning experiments.
Western blot analysis
Cells were rinsed with ice-cold HBSS and solubilized in
lysis buffer (50 mM Tris-HCl, pH 7.4, 1% Nonidet P-
40, 150 mM NaCl, 1 mM EDTA, 1 mM phenylmethyl-
sulfonyl fluoride, 10 µg/ml aprotinin, 5 µg/ml leupeptin,
and 1 mM sodium orthovanadate). Cell lysates were briefly
sonicated, centrifuged for 10 min at 4◦C, and boiled for
5 min in 2X sample buffer (20 mM Tris-HCl, pH 8.0,
2 mM EDTA, 2% SDS, 20 mM DTT, 0.1% bromophe-
nol blue, 20% glycerol) prior to loading. 50 µg protein
cell lysates were loaded and run on 7.5 or 10% SDS-
polyacrylamide gels followed by transfer to nitrocellulose
membranes (Amersham Pharmacia Biotech, Piscataway,
NJ). Membranes were blocked overnight in 5% non-
fat milk in TBS-T (20 mM Tris, 0.16 M NaCl, and
0.10% Tween-20, pH 7.4) at 4◦C. Membranes were in-
cubated in primary antibodies (Akt and Erk antibodies
1:2,000; pFKHRL1 1:500; and FKHR 1:1,000) in 5%
nonfat milk in TBS-T for 7–14 h at 4◦C, followed by
a 1 h incubation with secondary anti-rabbit HRP anti-
body (1:2000) at room temperature in 5% nonfat milk in
TBS-T. An enhanced chemiluminescent detection system
was utilized following the manufacturer’s protocol fol-
lowed by exposure to film (Hyperfilm-ECL, Amersham
Pharmacia Biotech). For phospho-FKHR immunoblot
analysis, SH-SY5Y cells were directly lysed in 300 µl
of 2X sample buffer, briefly sonicated, and centrifuged
for 10 min at 4◦C. 40 µl aliquots were boiled for 5 min
and loaded on SDS-polyacrylamide gels. For phosphatase
treatments, protein phosphatase I purchased from Cal-
biochem (San Diego, CA) was added directly to the cells
and incubated for 30–60 min at 30◦C prior to collection
of cell lysates. In some experiments, the nitrocellulose
membranes were stripped by incubation with stripping
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solution (2% SDS, 0.1 M dithiothreitol, and 0.1 M Tris,
pH 6.8). All blots were stained with Ponso-S to verify
equal loading of all wells. All experiments were repeated
at least 3 times and typical representative results are
shown.
Antibodies
Antibodies against FKHR, phospho-FKHR (serine 256),
phospho-p42/p44 MAP kinase, and phospho-Akt (ser-
ine 473) were purchased from Cell Signaling Technol-
ogy (Beverly, MA), while antibodies against FKHRL1
and phospho-FKHRL1 (serine 253) were purchased from
Upstate Biotechnology (Lake Placid, NY). Horseradish
peroxidase-conjugated polyclonal goat anti-rabbit anti-
body was purchased from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA), and ECL western blot reagents were pur-
chased from Amersham Pharmacia Biotech (Piscataway,
NJ).
Fluorescent microscopy
SH-SY5Y cells transfected with either pEGFP-C3-FKHR
or pEGFP-C3 vector were grown on coverslips for several
days, serum-starved for 5.5 h, followed by a 2 h treatment
with 10 nM IGF-I. After treatment, cells were fixed with
4% paraformaldehyde at room temperature, washed twice
with 1X phosphate-buffered saline (PBS), and counter-
stained with 1 µg/ml bisbenzamide in 1X PBS for 10 min.
Coverslips were mounted onto slides with Biomedia Gel
Mount (Electron Microscopy Sciences, Ft. Washington,
PA) and allowed to dry overnight. Fluorescent microscopy
analysis was performed using a Zeiss Axiophot micro-
scope. For leptomycin B experiments, cells were serum
starved, treated for 6 h with 20 nM leptomycin B, fol-
lowed by a 30 or 60 min 10 nM IGF-I exposure.
Flow cytometry
Hypodiploid (sub-Go) apoptotic analyses of SH-SY5Y
transfectants were performed in triplicate using propid-
ium iodide as previously described.8 Briefly, cells were
treated with or without 300 mM mannitol and with or
without IGF-I for 12 h and collected. Cells were fixed
using 70% ice cold ethanol and stained with 18 µg/mL
propidium iodide containing 40 µg/mL RNase A. Pro-
pidium iodide specifically intercalates into DNA, allow-
ing total DNA content to be measured for each cell. The
cells are then placed into each phase of the cell cycle based
on DNA content. Apoptotic cells characteristically have
DNA that is fragmented into 180–200 base-pair frag-
ments. These fragments are then represented as a sub-Go
peak on the cell cycle histogram using an Epics flow cy-
tometry system (Coulter Cytometry, Hialeah, FL).
Results
IGF-I stimulates the phosphorylation of FKHRL1
in SH-SY5Y human NBL cells
Our laboratory is interested in the mechanisms involved
in IGF-I mediated survival of human NBL cells. Although
increasing evidence points to a role for the forkhead tran-
scription factors in apoptosis, their function in NBL cells
has not been reported. Therefore, we examined endoge-
nous levels of FKHRL1 in SH-SY5Y human NBL cells, a
well-characterized cell line in which IGF-I acts as a potent
survival factor.8,9,48 Initial experiments utilized Western
blotting to examine the phosphorylation of FKHRL1, as
well as Akt and p42/p44 MAP kinases (Erks). SH-SY5Y
cells were serum starved overnight and then treated with
or without 10 nM IGF-I in serum-free media for either
30 min or 2 h. IGF-I treatment leads to Akt phosphory-
lation at Ser 473, a site required for Akt activation24 and
p42/p44 Erk phosphorylation by 30 min which continues
through 2 h (Figure 1). Thus, IGF-I induces a robust acti-
vation of both the PI3-K and MAP kinase pathways. In ad-
dition, IGF-I treatment produces a shift in electrophoretic
mobility in the FKHRL1 lanes (Figure 1). Treatment of
cells with protein phosphatase eliminates the upper band
in the FKHRL1 lanes (data not shown), confirming that
the mobility shift is caused by phosphorylation of the
protein. This phosphorylation was further confirmed by
Western blotting with a monoclonal antibody specific for
FKHRL1 phosphorylated at Ser 253, a site phosphory-
lated by Akt38,41–43 (Figure 1). Using densitometry, a 1.6
fold increase is observed in phospho-FKHRL1 protein lev-
els treated with IGF-I at both 30 min and 2 h timepoints
compared to lanes receiving no IGF-I.
FKHRL1 and FKHR phosphorylation
is dependent on PI3-K activity
Several studies suggest that the forkhead proteins are
regulated by the PI3-K pathway.37,38,42,43,49 Specifi-
cally, Akt, a key downstream effector of PI3-K, is
thought to either phosphorylate FKHR and FKHRL1
directly,37,38,40,43 or to promote their phosphorylation by
other kinases.37 To determine if PI3-K regulates these
proteins in SH-SY5Y cells, we examined the effect of a
PI3-K inhibitor, LY294002 (LY)50 on FKHRL1 phospho-
rylation. In these experiments, serum-starved SH-SY5Y
cells were treated with 0, 10, or 50 µM LY for 1 h prior
to a 30 min treatment with 1 or 10 nM IGF-I. As shown
in Figure 2A, treatment with 10 µM LY causes a signif-
icant reduction in the IGF-I stimulated phosphorylation
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Figure 1. IGF-I Promotes Phosphorylation of Endogenous FKHRL1 in SH-SY5Y Neuroblastoma Cells. SH-SY5Y neuroblastoma cells
were grown to approximately 75% confluency and serum starved overnight. Cells were treated with either 10 nM IGF-I or DMEM (0)
for 30 min and 2 h. 50 µg total protein of cell lysate was loaded in each lane and separated on a 7.5% polyacrylamide gel prior
to Western blotting for FKHRL1, phospho-Akt (Ser 473), phospho-Erk, or phospho-FKHRL1 (Ser 253). Arrows indicate the different
electrophoretic mobilities of the phosphorylated (asterisk ) and unphosphorylated forms of FKHRL1. All data are representative of 3
independent experiments.
Figure 2. IGF-I Mediated Phosphorylation of FKHR and FKHRL1
is Dependent on PI3-K Activation. SH-SY5Y cells were grown to
approximately 75% confluency and serum starved overnight. (A)
Cells were treated with 0, 10, or 50 µM LY for 1 h followed by a 0,
1, or 10 nM IGF-I treatment for 30 min. Western blot analysis was
performed as in Figure 1 for phospho-Akt (Ser 473), phospho-Erk,
and phospho-FKHRL1. (B) Cells were treated with 0 or 50 µM LY
for 1 h followed by a 0 or 1 nM IGF-I treatment for 30 min. Western
blot analysis was performed as in Figure 1 for phospho-Akt (Ser
473), phospho-Erk, and phospho-FKHR (Ser 256).
of Akt. Treatment with 50 µM LY, however, eliminates
the phosphorylation of Akt in IGF-I-stimulated cells. As
expected, IGF-I stimulated phosphorylation of Erks is un-
affected by LY, indicating that the MAP kinase pathway
remains activated despite full inhibition of PI3-K. In ad-
dition, pretreatment with 50 mM LY significantly reduces
the phosphorylation of FKHRL1 as evidenced by a shift
from the phosphorylated to the unphosphorylated form
(Figure 2A).
FKHR, another forkhead homolog, is also phospho-
rylated by Akt and is thought to play a role in growth
factor-stimulated survival.49 Similar to FKHRL1, IGF-I
enhances the phosphorylation of FKHR on Ser 256, a site
targeted by Akt (Figure 2B). Indeed, Akt phosphorylation
(Ser 473) is enhanced in parallel with FKHR phosphory-
lation. Further, IGF-I enhancement of both FKHR and
Akt phosphorylation is blocked by 50 µM LY. Specifi-
cally, phospho-FKHR levels of LY treated cells decreased
by 8-fold compared to cells receiving IGF-I only upon
densitometry analyses. As in Figure 2A, Erk phosphoryla-
tion is unaffected by LY. Together, these results show that
IGF-I stimulates the PI3-K-dependent phosphorylation
of Akt, FKHR, and FKHRL1 in human neuroblastoma
cells. However, the fact that MAPK pathway may also play
a role in the phosphorylation of FKHR and FKHRL1 can
not be completely ruled out.
Regulation of FKHR subcellular localization
in SH-SY5Y cells
In several cell lines, phosphorylation of FKHR and
FKHRL1 results in nuclear export, a process neces-
sary and sufficient for inhibition of their transcriptional
activity.40,43,49,51 To examine the effects of IGF-I on the
subcellular localization of forkhead proteins, cells were
transfected with pEGFP-C3-FKHR, a vector that ex-
presses FKHR fused to the C-terminus of a modified
variant of the Aequorea victoria green fluorescent pro-
tein. Fluorescence microscopy revealed that EGFP-FKHR
is localized equally between the nucleus and the cyto-
plasm in a population of asynchronous cells grown in
10% CS (Figures 3A and E). However, EGFP-FKHR is
predominantly localized to the nucleus when cells un-
dergo serum withdrawal for 5.5 h (Figures 3B and E) and
7.5 h (Figures 3C and E). Addition of 10 nM IGF-I to
serum-starved cells for 2 h results in an increase in cyto-
plasmic localization of EGFP-FKHR and a decrease in its
nuclear localization (Figures 3D and E) indicating that
IGF-I causes a rapid nuclear export of FKHR. Similar
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results are also observed after 1 h and 5 h treatments with
10 nM IGF-I (data not shown). In contrast, pEGFP-C3
vector transfected cells demonstrate diffuse (nuclear and
cytoplasmic) expression for each individual treatment in-
dicated above (data not shown).
Effects of FKHR overexpression on SH-SY5Y
apoptosis
Mutation of all three putative Akt phosphorylation
sites on FKHR or FKHRL1 results in a protein that
cannot be phosphorylated by Akt, thereby promoting
apoptosis.37,40 Therefore, overexpression of wild type
FKHR could alter the level of apoptosis in SH-SY5Y
cells. To examine this possibility, cells were transfected
with either FKHR or empty vector, and the degree of
apoptosis was determined after serum withdrawal in the
absence or presence of IGF-I. In these experiments, the
level of apoptosis was determined by propidium iodide
staining followed by flow cytometric analysis.8
Twelve h serum deprivation induces apoptosis in trans-
fected SH-SY5Y cells (Figure 4A). This correlates with
a low level of FKHR (Figure 1) or FKHRL1 (Figure
2) phosphorylation. Additionally, IGF-I prevents serum
withdrawal-induced apoptosis in the transfected cells,
which correlates with a high level of FKHR or FKHRL1
phosphorylation (Figures 1 and 2). Compared to the vec-
tor control, cells expressing EGFP-FKHR have a slightly
lower degree of apoptosis. Also, there is no difference
in the level of apoptosis in cells grown in 10% CS (T0)
(Figure 4A). Hyperosmotic media is a potent inducer of
apoptosis in SH-SY5Y cells and IGF-I prevents apoptosis
caused by this treatment.8,48 As expected, a 12 h treat-
ment with 300 mM mannitol produces higher levels of
apoptosis than 12 h of serum withdrawal (Figure 4A).
Furthermore, a lower degree of mannitol-induced apop-
tosis is observed in cells expressing EGFP-FKHR than
control cells. FKHR expression has no effect on IGF-I
protection or on the level of apoptosis in the presence
of 10% CS (T0). The above results suggest that FKHR
overexpression has a mildly protective effect on the induc-
tion of apoptosis in SH-SY5Y cells. To determine whether
this was due to an artifact of GFP or GFP-FKHR expres-
sion, apoptosis was examined in cells transfected with
an alternative FKHR construct, FKHR expressed with
an attached N-terminal FLAG peptide (pCMV-Tag2C-
FKHR). Overexpression of this construct again produces
a slight protective effect in serum withdrawal and hyper-
osmotic conditions (Figure 4B). Also, compared to con-
trol, FLAG-FKHR expression causes no difference in the
level of apoptosis in the presence of 10% CS (T0) or on
protection from apoptosis by IGF-I. Similar results are
also observed in both transfected cells lines at 24 and 48 h
(data not shown).
Phosphorylation of forkhead proteins
Akt translocates to the nucleus where it may associate with
and phosphorylate nuclear proteins such as transcription
factors to directly regulate gene transcription.25,30 Ge-
netic studies in C. elegans show that the forkhead transcrip-
tion factor DAF-16 interacts with Akt in the nucleus.31
However, it is unknown whether forkhead proteins are
phosphorylated in the nucleus or in the cytoplasm. One
mechanism by which cells can translocate from the nu-
cleus into the cytoplasm involves the CRM1 receptor spe-
cific for nuclear localization sequences found in various
proteins.52 Nuclear export of certain proteins is blocked
by the CRM1 inhibitor leptomycin B.53,54 Interestingly,
the localization of AFX, the third human forkhead ho-
molog, is altered with leptomycin B exposure.55 There-
fore, to determine whether phosphorylation and/or local-
ization of FKHR and FKHRL1 is affected by leptomycin
B exposure in human neuroblastoma cells, EGFP-FKHR
transfected SH-SY5Y cells were treated for 6 h with 20 nM
leptomycin B prior to stimulation with 10 nM IGF-I. Lep-
tomycin B exposure decreases the level of FKHRL1 phos-
phorylation in the presence of IGF-I in vector (1.5 fold)
and FKHR overexpressing cells (2.5 fold) using densitom-
etry analyses of Western blots (Figure 5A). However, lep-
tomycin B exposure of IGF-I treated FKHR overexpress-
ing cells resulted in no significant changes in phospho-
FKHR levels compared to cells receiving no leptomycin B
(Figure 5B). Lastly, leptomycin B prevents nuclear export
of FKHR in cells exposed to IGF-I (Figure 5C and D).
Taken together, these data suggest that nuclear export is
not necessary for FKHR phosphorylation in human NBL
cells. In contrast, nuclear export of the FKHRL1 may be
involved in the phosphorylation of this protein.
Discussion
Our laboratory is interested in IGF-I protection of
neuronal cells from apoptosis. We have previously
demonstrated that IGF-I prevents apoptosis of NBL
cells,8,48,56,57 Schwann cells,58,59 and neurons.60,61 Ac-
tivation of the PI3-K/Akt pathway is one way IGF-I pro-
tects cells from undergoing apoptosis.23,62,63 Recently,
forkhead transcription factors have been identified as po-
tential downstream effectors of the PI3-K/Akt pathway
that may mediate the survival activity of many growth
factors.37,38,41 Therefore, the goal of this study was to de-
termine whether forkhead transcription factors play a role
in IGF-I mediated cell survival of human NBL cells. These
studies focused on two of the most investigated forkhead
homologs, FKHR and FKHRL1.
In SH-SY5Y human NBL cells, IGF-I activates both
the PI3-K/Akt and the MAPK pathways as demon-
strated by the phosphorylation of Akt and p42/p44 Erks
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Figure 3. IGF-I Regulates the Cellular Localization of FKHR in SH-SY5Y Neuroblastoma Cells. Transfected SH-SY5Y cells were grown
to approximately 75% confluency in 10% CS. Cells were then treated as follows: (A) maintained in 10% CS, (B) serum-starved for 5.5 h,
(C) serum-starved for 7.5 h, (D) serum-starved for 5.5 h followed by 2 h with 10 nM IGF-I. After treatments, cells were fixed and analyzed
by fluorescent microscopy. (E) Percentage of cells with either nuclear or cytoplasmic localization of EGFP-FKHR for each individual
treatment. Results represent the mean percentage ± S.D. of three individual random counts of 200–300 cells per count.
Figure 5.
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Figure 4. Effect of EGFP-FKHR and FLAG-FKHR Overexpression on SH-SY5Y Apoptosis and Protection by IGF-I. SH-SY5Y neu-
roblastoma cells were grown to approximately 75% confluency in 10% CS prior to individual treatments (in triplicate). Apoptosis was
assayed using propidium iodide staining followed by flow cytometric analysis. Cells were deprived of serum for 12 h and then treated
for 12 h with either 10 nM IGF-I, 300 mM mannitol, or 300 mM mannitol plus 10 nM IGF-I. Percent apoptosis was assessed as the total
number of cells counted within a hypodiploid gate and is the mean ± SD (n = 3). T0 represents cells grown in 10% CS and not serum
deprived. (A) pEGFP-C3-FKHR and p-EGFP-C3 transfected cells. (B) pCMV-Tag 2C-FKHR and pCMV-Tag2C transfected cells.
respectively. These data are in agreement with our labora-
tory’s previous findings in SH-SY5Y cells.64−66 In addi-
tion, IGF-I induces the phosphorylation of the forkhead
proteins FKHRL1 and FKHR. Similarly, IGF-I has been
shown to promote the phosphorylation of FKHRL1 in hu-
man epithelial kidney cells37 and PC12 cells67 and FKHR
in 293 cells.38
Western blotting with selective monoclonal antibodies
reveals that IGF-I stimulates phosphorylation of FKHR
on Ser 256 and FKHRL1 on Ser 253. These data suggest
that IGF-I stimulates Akt-mediated phosphorylation of
FKHRL1 and FKHR in SH-SY5Y cells.37,42,44,67 Con-
sistent with the possibility that Akt phosphorylates these
sites, the phosphorylation of Akt, FKHRL1, and FKHR
is reduced in parallel by LY294002, a known inhibitor
of the PI3-K pathway. Such inhibition of growth factor-
stimulated forkhead phosphorylation by LY294002 also
occurs in primary human erythroid progenitor cells,68
human leukemic cells,44 and PC12 cells.67 These data
are in agreement with other studies demonstrating IGF-
I mediated phosphorylation of forkhead proteins via
Akt activation.67,69,70 Taken together, these data sug-
gest that IGF-I-stimulated phosphorylation of FKHR and
Figure 5. Effect of Leptomycin B Exposure on Phosphorylation and/or Localization of FKHR and FKHRL1. pEGFP-C3-FKHR transfected
SH-SY5Y cells (FKHR) or the empty vector (vector) were grown on 10 cm tissue culture plates or glass coverslips in 10% CS for several
days in media containing 10% calf serum. Cells were serum starved, treated for 6 h with 20 nM leptomycin B, followed by a 30 min 10
nM IGF-I exposure. (A) Western blot analysis for FKHRL1. Arrows represent the phosphorylated (*) and unphosphorylated bands. (B)
Western blot analysis for pFKHR. (C) Immunofluorescence of pEGFP-C3-FKHR cells exposed to IGF-I only. (D) Immunofluorescence
of pEGFP-C3-FKHR cells exposed to leptomycin B and IGF-I.
FKHRL1 is dependent on activation of the PI3-K/Akt
pathway.
Unphosphorylated forkhead transcription factors are
found primarily in the nucleus where they can bind to
several DNA domains.37,71,72 However, several studies
show that Akt-dependent phosphorylation of forkhead
corresponds with their export from the nucleus.37,43,47
Mutation of Akt phosphorylation sites on FKHRL1 and
FKHR prevents phosphorylation, causing accumulation
of these proteins in the nucleus.37,47 Similarly, epider-
mal growth factor stimulates both the phosphorylation
and nuclear export of FKHR.73 Using a GFP fusion pro-
tein, we now show that IGF-I stimulates the export of
FKHR from the nucleus into the cytoplasm in human
NBL cells. FKHR is expressed in both the nucleus and
cytoplasm in NBL cells maintained in 10% CS, while
serum withdrawal results in accumulation of FKHR in
the nucleus. In addition, our laboratory has recently
shown IGF-I mediated phosphorylation and nuclear ex-
clusion of FKHR in rat embryonic dorsal root ganglia
neurons.74
Next, we wanted to determine if overexpression of
FKHR has any effect on levels of apoptosis in cells exposed
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to hyperosmotic treatment. Overexpression of wild type
FKHR has no effect on the survival activity of IGF-I, as
shown previously by Brunet et al.37 Wild type FKHR ap-
pears to provide weak protection from serum withdrawal
or mannitol-induced apoptosis. Whether or not this pro-
tective effect is significant, it contrasts with the ability
of wild type FKHR to induce apoptosis in 293T cells.40
In addition, other investigators report that only overex-
pression of the forkhead phosphorylation mutants leads
to apoptosis.37,40 Therefore, it is possible that wild type
FKHR does not normally play a major role in the apop-
tosis of SH-SY5Y cells. Rather, its physiological role in
these cells may be in mediating growth factor-stimulated
transcription.
One mechanism of nuclear export of proteins involves
the CRM1 receptor. Biggs and coworkers43 utilized lepto-
mycin B to show that CRM1 mediates this export of fork-
head proteins from the nucleus. Therefore, we wanted to
investigate the effects of IGF-I on the cellular localization
of FKHR utilizing leptomycin B in human NBL cells.
Leptomycin B prevents IGF-I-stimulated FKHR nuclear
export, indicating a role for CRM1 in this process. In
addition, leptomycin B treatment had no effect on the
phosphorylation of FKHR in transfected cells. These data
agree with the observations that activated Akt is trans-
ported to the nucleus where it can interact and phosphory-
late forkhead proteins.30,38,75 In fact, Akt associates with
forkhead proteins in the nucleus in C. elegans.31 How-
ever, leptomycin B decreases the level of FKHRL1 phos-
phorylation in FKHR transfected cells exposed to IGF-I.
These data suggest that the phosphorylation of the fork-
head homologs in human NBL cells may involve different
mechanisms.
In conclusion, our data show that IGF-I exposure phos-
phorylates two forkhead homologs, FKHR and FKHRL1,
in human NBL cells via a PI3-K/Akt pathway. In addi-
tion, IGF-I exposure causes accumulation of FKHR in
the cytoplasm, while serum withdrawal causes accumu-
lation of FKHR in the nucleus. Overexpression of wild
type FKHR does not lead to increased apoptosis in cells
exposed to hyperosmotic treatment when compared with
vector transfected cells. Lastly, leptomycin B does not af-
fect phosphorylation of FKHR and FKHRL1 while also
blocking nuclear export of cells exposed to IGF-I.
Functional apoptotic studies suggest that forkhead ho-
mologs promote cellular apoptosis by inducing genes
responsible for cell death such as the Fas ligand.37,40
However, mannitol may not induce Fas ligand, therefore
explaining the apoptosis data in the current study. We
are currently investigating other types of apoptotic stim-
uli in our FKHR transfected cells including traditional
chemotherapeutic drugs and radiation treatment. Other
apoptotic inducers, potentially acting through a Fas me-
diated pathway, may indicate a more definitive role for the
forkhead proteins in the apoptosis of human NBL cells.
Conclusion
IGF-I induced phosphorylation of Erks (p42/p44), FKHR
(Ser 253), FKHRL1 (Ser 256), and Akt (Ser 473). PI3-
K inhibitor, LY294002, reduced IGF-I-stimulated phos-
phorylation of FKHR, FKHRL1, and Akt, but did not af-
fect Erk phosphorylation. Using a GFP-FKHR construct,
FKHR imported into the nucleus during growth factor
withdrawal-induced apoptosis. In addition, IGF-I rescue
from serum withdrawal-induced apoptosis is associated
with a rapid export of GFP-FKHR into the cytoplasm. An
inhibitor of CRM1-mediated nuclear export, leptomycin
B, decreased the phosphorylated levels of FKHRL1, while
having no effect on the phosphorylation status of FKHR.
Leptomycin B also prevented IGF-I stimulated nuclear ex-
port of GFP-FKHR. These studies show IGF-I phospho-
rylation of FKHR and FKHRL1 via a PI3-K-dependent
pathway in NBL cells.
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